Vigil Neuroscience Beheer

Beheer criteriumcontroles 2/4

De CEO Vigil Neuroscience is Ivana Magovcevic-Liebisch, benoemd in Jul2020, heeft een ambtstermijn van 4.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.85M, bestaande uit 15.2% salaris en 84.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.52% van de aandelen van het bedrijf, ter waarde $ 682.34K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 3.6 jaar.

Belangrijke informatie

Ivana Magovcevic-Liebisch

Algemeen directeur

US$3.8m

Totale compensatie

Percentage CEO-salaris	15.2%
Dienstverband CEO	4.3yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	3.6yrs

Recente managementupdates

Recent updates

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

Oct 17

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

May 30

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Feb 01

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Oct 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Jun 27

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Mar 14

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Nov 29

Analyse CEO-vergoeding

Hoe is Ivana Magovcevic-Liebisch's beloning veranderd ten opzichte van Vigil Neuroscience's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$83m
Jun 30 2024	n/a	n/a	-US$84m
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$4m	US$585k	-US$83m
Sep 30 2023	n/a	n/a	-US$79m
Jun 30 2023	n/a	n/a	-US$76m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$4m	US$557k	-US$68m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$50m
Dec 31 2021	US$3m	US$450k	-US$43m
Dec 31 2020	US$3m	US$204k	-US$57m

Compensatie versus markt: De totale vergoeding ($USD 3.85M ) Ivana } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Ivana is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ivana Magovcevic-Liebisch (57 yo)

4.3yrs

Tenure

US$3,847,287

Compensatie

Dr. Ivana Magovcevic-Liebisch, Ph. D., J. D., serves as a Director of Quanterix Corporation since October 2024. She serves as an Independent Director of Acrivon Therapeutics, Inc. since February 08, 2024....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ivana Magovcevic-Liebisch	President	4.3yrs	US$3.85m	0.52% $ 682.3k
Jennifer Ziolkowski	Chief Financial Officer	3.7yrs	US$1.70m	0.010% $ 13.1k
David Gray	Chief Scientific Officer	1.8yrs	US$2.77m	0% $ 0
Sharon Morani	Senior Director of Facilities & Operations	1.8yrs	geen gegevens	geen gegevens
Eric Brophy	Senior Manager of Information Technology	no data	geen gegevens	geen gegevens
Leah Gibson	Vice President of Investor Relations and Corporate Communications	no data	geen gegevens	geen gegevens
April Effort	VP & Head of Corporate Development	2.8yrs	geen gegevens	geen gegevens
Evan Thackaberry	Senior VP & Head of Early Development	4.2yrs	geen gegevens	0.0038% $ 4.9k
Christian Mirescu	Senior VP & Head of Neuroimmunology	2.8yrs	geen gegevens	geen gegevens
Weeteck Yeo	Senior Vice President of Strategic Operations	2.8yrs	geen gegevens	geen gegevens
Jessica Stromme	Senior Vice President of Program Leadership & Portfolio Management	2.8yrs	geen gegevens	geen gegevens
Ali Toumadj	VP & Head of Medical Sciences	1.8yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VIGL wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ivana Magovcevic-Liebisch	President	4.3yrs	US$3.85m	0.52% $ 682.3k
Suzanne Bruhn	Independent Director	2.3yrs	US$138.50k	0% $ 0
Cheryl Blanchard	Independent Director	4yrs	US$140.00k	0% $ 0
Mary Thistle	Independent Director	2.6yrs	US$143.83k	0% $ 0
Ole Isacson	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Bruce Booth	Independent Chairman of the Board	4.4yrs	US$165.00k	0% $ 0
Marco Colonna	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Gerhard Koenig	Independent Director	4.3yrs	US$136.33k	0% $ 0
Bradley Hyman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stefan Vitorovic	Independent Director	3.3yrs	US$136.83k	0.066% $ 85.7k
Jaime Grutzendler	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Dunlop	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VIGL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Vigil Neuroscience Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

General Counsel & Corporate Secretary notifies of intention to sell stock

Vigil Neuroscience, Inc., Annual General Meeting, Jun 05, 2024

Vigil Neuroscience, Inc. Announces Executive Changes

Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer

Vigil Neuroscience, Inc. Appoints Samantha Budd Haeberlein to Its Board of Directors

Vigil Neuroscience, Inc. Announces Resignation of Shaan Gandhi, from Member of Board of Directors

Recent updates

Price target increased by 9.8% to US$17.57

We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully

General Counsel & Corporate Secretary notifies of intention to sell stock

Vigil Neuroscience, Inc. Announces U.S. Food and Drug Administration Removal the Partial Clinical Hold on its Ongoing Phase 1 Clinical Trial of VG-3927

New major risk - Financial position

Vigil Neuroscience, Inc. Announces Interim Data from Its Ongoing Phase 1 Clinical Trial Evaluating Vv-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Vigil Neuroscience, Inc. Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell Small Cap Comp Value Index

Vigil Neuroscience, Inc. announced that it expects to receive $39.99997 million in funding from Sanofi Pasteur Biologics, LLC, Aventis Inc.

Vigil Neuroscience, Inc. announced that it has received $3.999997 million in funding from Sanofi Pasteur Biologics, LLC

New major risk - Share price stability

We're Keeping An Eye On Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Rate

New major risk - Revenue and earnings growth

Price target increased by 8.4% to US$18.57

New minor risk - Market cap size

Vigil Neuroscience, Inc., Annual General Meeting, Jun 05, 2024

Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting

New minor risk - Shareholder dilution

Price target increased by 10% to US$18.86

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces Executive Changes

New minor risk - Market cap size

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

New minor risk - Market cap size

Price target decreased by 14% to US$17.13

Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

New major risk - Revenue and earnings growth

Vigil Neuroscience, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating Vv-3927, a Small Molecule Trem2 Agonist, for Potential Treatment of Alzheimer's Disease

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?

Vigil Neuroscience, Inc Provides an Update on the Small Molecule TREM2 Agonist, VG-3927

Vigil Neuroscience, Inc. Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for Vgl101 for the Treatment of ALSP

Vigil Neuroscience, Inc. Presents VGL101 Complete Phase 1 Data and Phase 2 Ignite Trial Design at the 2023 American Neurological Association Annual Meeting

New major risk - Share price stability

Vigil Neuroscience, Inc. Appoints Christopher J. Silber, M.D. as Chief Medical Officer

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Appoints Samantha Budd Haeberlein to Its Board of Directors

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Vigil Neuroscience, Inc. Announces Resignation of Shaan Gandhi, from Member of Board of Directors

High number of new and inexperienced directors

Vigil Neuroscience, Inc. Announces Executive Changes

Here's Why We're Not Too Worried About Vigil Neuroscience's (NASDAQ:VIGL) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP

Vigil draws bullish view at Wedbush on upcoming readout for lead asset

Vigil Neuroscience, Inc. announced that it has received $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience, Inc. announced that it expects to receive $74.999705 million in funding from Deep Track Capital, LP, BVF Partners L.P., Deerfield Management Company, L.P. Series C, Dafna Capital Management, LLC, The Invus Group, LLC

Vigil Neuroscience announces $75M PIPE financing

Vigil Neuroscience Appoints Suzanne Bruhn to Its Board of Directors

We're Hopeful That Vigil Neuroscience (NASDAQ:VIGL) Will Use Its Cash Wisely

Vigil Neuroscience, Inc.(NasdaqGS:VIGL) dropped from Russell 2000 Growth Index

Vigil Neuroscience, Inc. Expands VGL101 Phase 1 Trial to Australia

Vigil Neuroscience, Inc. Appoints Christopher Verni as General Counsel and Mary Thistle to Its Board of Directors

Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Invest In Growth?

Vigil Neuroscience, Inc. has completed an IPO in the amount of $98 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd